Disease · MONDO_1060198

ischemic stroke

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ischemic stroke. Diseases, record MONDO_1060198. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_1060198

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ischemic stroke; Open Targets
Open Targets ID: MONDO_1060198; Open Targets
Other names: ischaemic stroke; Open Targets
Disease Ontology: DOID:0051062; Disease Ontology
Highest stage of its drugs: Approval, for 6 of its 213 drugs, from PMDA and TTD; Open Targets

Drugs213

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	PMDA	11	10	8	Drugs and targets
EDOXABAN	CHEMBL1269025	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
APIXABAN	CHEMBL231779	Small molecule	Approval	PMDA	9	8	6	Drugs and targets
VINPOCETINE	CHEMBL71752	Small molecule	Approval	TTD	2	1	1	Drugs and targets
DABIGATRAN ETEXILATE	CHEMBL539697	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
MAGNESIUM	CHEMBL1201230	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 3	ClinicalTrials.gov	78	78	58	Drugs and targets
TENECTEPLASE	CHEMBL2108791	Enzyme	Phase 3	ClinicalTrials.gov	47	47	46	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	36	36	36	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets

1 to 10 of 213

See all 213 drugs

Targets263

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
ADRB1	Adrenergic receptor	5	Adrenergic receptor agonist; Adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
P2RY12	P2Y purinoceptor 12	5	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/64805	Drugs and targets
PDE5A	3',5'-cyclic phosphodiesterase	5	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets
SERPINC1	Antithrombin-III	5	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
ADRB2	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	4	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	4	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets

1 to 10 of 263

See all 263 targets

Trials377

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 37 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05395351	Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization		113,035	2024-12-20	Stroke	ALTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT04915729	A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity	Phase 3	1,489	2024-12-10	Stroke	ALTEPLASE, TENECTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT01369069	Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial	Phase 3	1,151	2019-12-16	Acute Ischemic Stroke, Diabetes, Hyperglycemia	INSULIN HUMAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02930018	Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke	Phase 3	1,105	2020-12-14	Stroke, Acute	NERINETIDE	Its record names the disease	ClinicalTrials.gov
NCT04462536	Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis	Phase 3	850	2025-06-22	Stroke, Acute	NERINETIDE	Its record names the disease	ClinicalTrials.gov
NCT00235495	Albumin in Acute Ischemic Stroke Trial	Phase 3	841	2019-09-11	Ischemic Stroke	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00359424	Interventional Management of Stroke (IMS) III Trial	Phase 3	656	2013-12-13	Stroke	ALTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT03735979	Multi-arm Optimization of Stroke Thrombolysis	Phase 3	514	2024-11-19	Acute Ischemic Stroke	ARGATROBAN, EPTIFIBATIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01582854	Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)	Phase 3	503	2016-02-22	Post-Stroke Cognitive Impairment (PSCI)	ACTOVEGIN	Its record names the disease	ClinicalTrials.gov
NCT03151993	Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS	Phase 3	336	2025-04-02	Ischemic Stroke	ALTEPLASE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 377

See all 377 trials

Comparisons in its trials124

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Acute Ischemic Stroke (AIS) Patients Aged >80 Years Who Received IV Rt-PA (Alteplase) vs Acute Ischemic Stroke (AIS) Patients Aged 18 to 80 Years Who Received IV Rt-PA (Alteplase): Number of Patients With Stroke Recurrence During Hospitalization	369 of 3,332	2,039 of 28,086	31,418	NCT05395351	Trial comparisons
Alteplase Active Control Group vs Tenecteplase Treatment Group: deaths from any cause	44 of 736	34 of 732	1,468	NCT04915729	Trial comparisons
Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events	115 of 736	116 of 732	1,468	NCT04915729	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL)	15 of 581	0 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Death	54 of 581	65 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: deaths from any cause	54 of 581	65 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable Modified Rankin Scale (Yes/No)	119 of 581	123 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: serious adverse events	209 of 581	198 of 570	1,151	NCT01369069	Trial comparisons
Nerinetide, 2.6 mg/kg vs Placebo: Mortality Rate	64 of 549	74 of 556	1,105	NCT02930018	Trial comparisons
Nerinetide, 2.6 mg/kg vs Placebo: deaths from any cause	64 of 549	74 of 556	1,105	NCT02930018	Trial comparisons

1 to 10 of 124

See all 124 comparisons in its trials

Papers from its trials462

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41778584	RESULT	1	PubMed
40426210	RESULT	1	PubMed
38914085	RESULT	1	PubMed
37256974	RESULT	1	PubMed
37231200	RESULT	1	PubMed
36941074	RESULT	1	PubMed
36938708	RESULT	1	PubMed
36711206	RESULT	1	PubMed
36693725	RESULT	1	PubMed
36475464	RESULT	1	PubMed

1 to 10 of 462

See all 462 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_1060198

GET https://conductscience.org/api/diseases/v1/MONDO_1060198/drugs?page=2

API reference For AI assistants